NMN — Nicotinamide Mononucleotide — is a naturally occurring nucleotide with molecular formula C₁₁H₁₅N₂O₈P (CAS: 1094-61-7, molecular weight: 334.22 g/mol). It is a member of the vitamin B3 family and a direct biosynthetic precursor to NAD+ (Nicotinamide Adenine Dinucleotide).

NAD+ is a coenzyme present in every cell of the human body. It serves as a critical electron carrier in energy metabolism (oxidative phosphorylation), a substrate for sirtuins (NAD+-dependent protein deacylases involved in gene regulation and DNA repair), and a substrate for PARPs (poly-ADP-ribose polymerases involved in DNA damage repair). Sirtuins cannot function without adequate NAD+.

Research has consistently demonstrated that NAD+ levels decline with age in animal models and in humans. 📚 Verdin, Science 2015 estimated a roughly 50% decline in tissue NAD+ levels between youth and middle age in mammals. This decline is theorised to contribute to reduced mitochondrial function, increased genomic instability and other hallmarks of cellular ageing.

NMN is taken as a supplement because it can raise NAD+ levels via the salvage biosynthesis pathway. It is converted to NAD+ more efficiently than supplemental NAD+ itself — because NAD+ cannot cross cell membranes directly, whereas NMN has a dedicated intestinal transporter (Slc12a8, identified by Grozio et al., Nature Metabolism, 2019).

NMN is found naturally in small amounts in several foods — broccoli, edamame, avocado, cucumber and raw beef — but dietary amounts are insufficient to meaningfully raise NAD+ levels, which is the rationale for supplementation.

Human trial evidence on NMN has expanded substantially since 2020. The following are the key published trials as of mid-2026:

Yoshino et al., Cell Metabolism, 2021 — 250mg NMN daily for 10 weeks in postmenopausal women with prediabetes and overweight. Showed improved skeletal muscle insulin sensitivity and signalling. First RCT to demonstrate a metabolic effect of NMN in humans. 📚 PubMed 34015196

Irie et al., NPJ Aging, 2020 — 100, 250 or 500mg single oral doses in healthy Japanese men. Confirmed NMN raises NAD+ metabolites in blood in a dose-dependent manner. No adverse effects. First human pharmacokinetic data for NMN. 📚 PubMed 33378646

Liao et al., Journal of the International Society of Sports Nutrition, 2021 — 300mg NMN daily for 6 weeks in amateur runners aged 27–50. Showed improved aerobic capacity (VO₂ max) compared to placebo. 📚 PubMed 34514983

Huang et al., 2022 — 600–1200mg NMN daily for 60 days in middle-aged adults. Showed increases in blood NAD+ levels. Generally well tolerated.

Multicentre RCT (2023) — 300, 600 and 900mg doses over 60 days. Showed improvements in cardiovascular markers including LDL cholesterol, body weight and blood pressure at higher doses. 📚 Referenced in Rollingstone, 2026

Where the evidence stops: All human trials to date have been short (4–12 weeks), relatively small, and used varying doses and populations. No long-term human trials (1 year+) exist. The animal evidence is substantially stronger than human evidence. Most of the longevity-specific claims attributed to NMN (slowing ageing, extending lifespan) have only been demonstrated in animal models.

Published human trials have used doses ranging from 100mg to 2,000mg per day. The most common range across published studies is 250–900mg daily. There is no established optimal human dose — this remains an active area of research.

Key dose ranges from published trials:

100–500mg single doses — Irie et al., 2020 (pharmacokinetics, safety). 250mg daily — Yoshino et al., 2021 (insulin sensitivity). 300mg daily — Liao et al., 2021 (aerobic capacity). 600–1,200mg daily — Huang et al., 2022. 300–900mg daily — multicentre 60-day RCT, 2023. 2,000mg daily for 2 weeks — 2023 trial, well tolerated. 📚 Examine.com NMN database, 2025

Safety ceiling from current data: Up to 1,200mg/day for 6 weeks and 900mg/day for 8 weeks have been well tolerated with no serious adverse effects reported. The 2,000mg/day 2-week trial also found no serious adverse effects.

Important context: Earlier NMN research used lower doses partly due to production cost constraints. More recent trials have moved toward higher doses. The relationship between dose and effect in humans is still being characterised. Animal research used doses that would translate to significantly higher human-equivalent doses than most supplements currently provide.

No published human trial has directly compared morning vs evening NMN timing on primary outcomes. The morning recommendation is a reasonable inference from the biology rather than a trial-proven conclusion.

The biological rationale for morning dosing: NAD+ is centrally involved in circadian rhythm regulation via the CLOCK-BMAL1 transcriptional feedback loop. NAMPT — the rate-limiting enzyme in the NMN biosynthesis pathway — shows circadian oscillation, with peak activity during the day. Sirtuins (SIRT1 and SIRT3), which depend on NAD+ for activity, are also subject to circadian regulation. Taking NMN in the morning may align supplementation with the body's natural NAD+ activity cycle. 📚 Peek et al., Cell Metabolism 2013 — circadian NAD+

Anecdotal reports of sleep disruption with evening dosing: Some users report difficulty sleeping when taking NMN late at night — consistent with NAD+'s role in circadian signalling — but this has not been formally studied.

What published trials used: Most human NMN trials instructed participants to take NMN in the morning, typically with food. This was pragmatic rather than optimisation-driven.

The theoretical case for sublingual NMN is well established — dissolving NMN under the tongue allows absorption through the oral mucosa directly into systemic circulation, bypassing first-pass hepatic metabolism. This route is used for several pharmaceutical compounds precisely because it avoids hepatic degradation.

However, a directly countervailing finding complicates the picture. Grozio et al. (Nature Metabolism, 2019) identified Slc12a8 — a dedicated NMN transporter protein in the intestinal brush border — that actively shuttles NMN intact into intestinal cells and from there into circulation. This suggests oral NMN is not as dependent on passive diffusion as previously assumed, and that standard oral capsule absorption may be more efficient than the pre-2019 consensus suggested. 📚 Grozio et al., Nature Metabolism 2019

No published head-to-head human trial has directly compared sublingual vs oral capsule NMN bioavailability or downstream NAD+ levels. Such a comparison would be valuable but has not yet been published.

Practical advantage of sublingual powder: Pure NMN powder dissolved under the tongue provides a real-time purity indicator. Genuine β-NMN has a distinctive clean, zesty, lightly citrus taste that is consistent across batches. Flavourless powder suggests filler dilution. Noticeably bitter taste suggests B3 Nicotinamide substitution. This taste-test cannot be performed with capsules.

NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are both NAD+ precursors and both demonstrably raise NAD+ levels in humans. Understanding the metabolic relationship between them helps clarify the comparison.

Metabolic pathway: NR → NMN → NAD+. NMN is therefore one metabolic step closer to NAD+ than NR. The discovery of Slc12a8 (Grozio et al., 2019) demonstrated that NMN can be absorbed intact by intestinal cells without first converting to NR — suggesting a more direct route to NAD+ for NMN.

Where NMN has stronger published evidence: Aerobic capacity (Liao et al., 2021), insulin sensitivity (Yoshino et al., 2021), and telomere length research. The volume of published human trials currently slightly favours NMN.

Where NR has stronger published evidence: Brain health and neuroprotection. Published data exists on NR and markers of neurodegenerative disease that does not yet exist for NMN. NR is also classified as Generally Recognized as Safe (GRAS) by the FDA — the NMN regulatory situation in the US is more complicated (not relevant to UK buyers). 📚 Martens et al., Nature Communications 2018 — NR in older adults

Direct comparison trials: Very few direct head-to-head human trials comparing NMN and NR on the same endpoints exist. Most comparisons are indirect, drawn from separate trials using different populations, doses and outcomes.

NMN purity verification matters because the most common adulteration — B3 Nicotinamide (Niacinamide) — produces a white crystalline powder visually identical to NMN but with no NAD+ precursor activity. It is substantially cheaper to manufacture. Four practical tests can be applied before committing to a purchase:

Test 1 — Capsule size: A genuine 500mg NMN capsule requires a Size 0 capsule shell at minimum. This is the smallest shell physically capable of holding 500mg of crystalline NMN powder. A smaller capsule (Size 1 or 2) cannot hold a genuine 500mg fill and indicates underfilling or substitution.

Test 2 — Capsule weight: Place a single capsule on a milligram-accurate digital scale. 590–620mg indicates pure NMN (500mg) plus Size 0 HPMC shell (~90mg). A reading of 700mg or above indicates the presence of fillers — Microcrystalline Cellulose (MCC) or Dicalcium Phosphate (DCP) — which do not contribute to NMN content.

Test 3 — Taste test: Open a capsule and place a small amount on the tongue. Pure β-NMN has a distinctive, clean, zesty, lightly citrus-like taste with no significant bitterness and no chalky residue. A flavourless result indicates heavy filler dilution. A noticeably bitter taste is consistent with B3 Nicotinamide substitution, which has a distinctly bitter profile.

Test 4 — Dissolve test: Empty a capsule into a glass of cold water and stir for 20 seconds. Pure NMN dissolves completely and rapidly — water should clear within 30–60 seconds with minimal sediment. MCC and DCP do not dissolve in cold water and will produce persistent cloudiness or white sediment if present.

Laboratory verification: Request the Certificate of Analysis (CoA) for the specific batch you purchased from an accredited independent laboratory — ideally Eurofins or equivalent. HPLC (High Performance Liquid Chromatography) analysis is the standard verification method for NMN purity and identity.

Two specifications matter above all others when evaluating NMN purity: the isomeric form and the purity percentage.

Isomeric form — β-NMN is the active form: NMN exists as two isomers — alpha (α-NMN) and beta (β-NMN). Only β-NMN is the biologically active form found naturally in the body and studied in human clinical trials. All published human NMN research has used β-NMN. The CAS number for β-NMN is 1094-61-7. Suppliers should be able to confirm this CAS number. If they cannot, do not purchase.

Purity percentage — 99%+ minimum: The most credible NMN supplements declare 99%+ purity. Better suppliers declare 99.9%+. Purity should be confirmed by HPLC analysis from a named accredited independent laboratory. A declaration on a label without independent verification is not confirmation of purity.

What to look for on a CoA: The assay result (purity %), the test method (HPLC), the specific compound tested (β-Nicotinamide Mononucleotide), the CAS number (1094-61-7), the batch number matching your product, and the testing laboratory name and accreditation status.

Charge Products NMN is 99.99% pure β-NMN (CAS 1094-61-7) — independently verified by Eurofins per batch. Certificate of Analysis available on request for both our NMN 500mg capsules and NMN powder.

Yes. NMN is legal to sell and purchase as a food supplement in the UK as of June 2026. It is not a controlled substance. It is not classified as a medicine by the MHRA. It does not require a prescription.

Novel Food status: The UK Food Standards Agency (FSA) is currently reviewing NMN under Novel Food regulations. Novel Food status requires authorisation for sale if a food or ingredient was not consumed to a significant degree in the EU before May 1997. The NMN Novel Food consultation is ongoing as of June 2026 — NMN has not been restricted and remains on the market.

Authorised health claims: NMN has no authorised health claims under UK or EU retained nutrition claim regulations (Regulation No 432/2012). It must be sold as a food supplement only. No therapeutic, medicinal, diagnostic or preventative claims may be made for NMN supplements in the UK.

The US FDA situation is different and does not affect UK law or UK buyers. In the US, the FDA has raised questions about NMN's status following pharmaceutical submissions — this regulatory context is specific to the US market.

NMN and sport: According to the 2026 WADA (World Anti-Doping Agency) Prohibited Substances List, NMN is not a prohibited substance.

Short-term safety data from published human trials is reassuring. No serious adverse effects have been reported in trials using doses up to 1,200mg/day for 6 weeks 📚 Irie et al. 2020, 900mg/day for 8 weeks, or 2,000mg/day for 2 weeks 📚 2023 trial referenced in Examine 2025. The most common minor adverse effects noted across trials were mild gastrointestinal symptoms at higher doses, which resolved without intervention.

Limitations of current safety data: All published human trials have been short — 4 to 12 weeks. No long-term human safety data exists beyond this window. The safety profile of sustained daily NMN supplementation over years, at higher doses, or in specific patient populations remains unstudied in humans. Long-term data is needed before robust safety conclusions can be drawn for extended use.

Populations where caution is warranted:

Pregnancy and breastfeeding — not recommended. No safety data in pregnant or lactating women. Animal studies have not been conducted to establish safety parameters in these groups. 📚 Examine.com NMN 2025

Active cancer — some researchers have raised theoretical questions about whether boosting NAD+ could affect tumour cell metabolism, given that cancer cells have elevated NAD+ demands. This has not been studied clinically and remains speculative, but warrants discussion with an oncologist before NMN use if relevant.

Drug interactions — no published human interaction studies between NMN and any medication exist. This is not evidence of safety in combination — it is an evidence gap. Anyone on prescription medication should consult their GP or pharmacist before taking NMN.

Under 18 — no paediatric safety data. Not recommended.